GLP-1, GLP-2, and GLP-3 Receptors

GLP-1R: Receptor and Tissue Distribution

The GLP-1 receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) with a large extracellular N-terminal ligand-binding domain. Its expression is notably broad: pancreatic beta cells and alpha cells, multiple hypothalamic nuclei (arcuate and paraventricular), the nucleus of the solitary tract in the brainstem, vagal afferent terminals in the gut wall, cardiac myocytes, vascular endothelium, renal tubular epithelium, and the enteric nervous system. This wide distribution means that a single agonist molecule can trigger effects simultaneously across metabolic, neurological, cardiovascular, and renal domains.

Intracellular Signalling: Gs → cAMP → PKA

GLP-1R agonism activates the Gs subunit, which stimulates adenylyl cyclase to convert ATP to cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA) and exchange proteins directly activated by cAMP (EPACs). In pancreatic beta cells, this cascade phosphorylates voltage-gated calcium channels, drives calcium influx, and triggers glucose-dependent insulin exocytosis. The glucose-dependence is mechanistically important: calcium influx requires prior partial depolarisation by elevated intracellular glucose, meaning GLP-1R agonists cannot force insulin release in the absence of adequate blood glucose, the basis of their low intrinsic hypoglycaemia risk.

Downstream Effects: Metabolic, Central, and Cardiovascular

Across its many target tissues, GLP-1R activation produces: glucose-dependent insulin secretion (beta cells); suppression of inappropriate glucagon release (alpha cells, also glucose-dependent); slowing of gastric emptying via enteric and vagal GLP-1R, blunting postprandial glucose excursions; central appetite suppression in the hypothalamus by inhibiting NPY/AgRP hunger-driving neurons and activating POMC/CART satiety neurons; modulation of mesolimbic reward circuitry, reducing hedonic food intake; and cardioprotective effects via direct GLP-1R signalling in cardiac and vascular tissue, as demonstrated in the SELECT trial (20% relative MACE reduction with semaglutide in non-diabetic patients with established cardiovascular disease).

Pharmacological Examples

GLP-1R is the pharmacological target of semaglutide (Ozempic, Wegovy, mono-agonist), liraglutide (Victoza, Saxenda, mono-agonist), tirzepatide (Mounjaro, Zepbound, GLP-1R + GIPR dual agonist), and retatrutide (GLP-1R + GIPR + glucagon receptor triple agonist, investigational). All act through the same Gs–cAMP–PKA cascade; differences in clinical profile reflect additional receptor targets, half-life, and structural differences.

GLP-2R: A Gut-Restricted Receptor

The GLP-2 receptor (GLP-2R) is also a class B GPCR, but its tissue expression is strikingly narrow compared to GLP-1R. GLP-2R expression is concentrated in the intestinal epithelium (particularly the small intestine), subepithelial myofibroblasts, enteric neurons, and intestinal endocrine cells. Extraintestinal expression exists in limited areas, some expression is detected in the brain and pancreas, but it is substantially lower than in the gut. This restricted distribution is the molecular basis for GLP-2's organ-selective actions: a GLP-2 agonist targets the intestine with a specificity that GLP-1 agonists, with their broad receptor distribution, do not.

Mechanism: Intestinal Proliferation and Barrier Integrity

GLP-2R activation via Gs–cAMP signalling in intestinal epithelial cells and subepithelial myofibroblasts drives enterocyte proliferation (increased crypt cell mitosis) and reduces apoptosis, producing a net increase in intestinal mucosal surface area. Additional effects include increased villus height, enhanced nutrient absorption capacity, improved intestinal barrier integrity (reduced permeability), and increased mucosal blood flow. GLP-2 has also been shown to stimulate intestinal gluconeogenesis in the portal circulation and modulate gut motility via enteric neurons. These actions are directly relevant to conditions involving intestinal atrophy, short bowel syndrome, and mucosal inflammation.

Pharmacological Example: Teduglutide

Teduglutide (Gattex in the US, Revestive in Europe) is a DPP-4-resistant GLP-2 analogue approved for adult and paediatric short bowel syndrome (SBS). In SBS patients dependent on parenteral nutrition, teduglutide increases intestinal absorptive capacity, enabling reduction in parenteral nutrition volume. The mechanism is direct GLP-2R stimulation on the residual intestinal mucosa, promoting adaptive growth of the remaining bowel. Notably, teduglutide does not cause weight loss or metabolic effects in the way GLP-1 agonists do, consistent with the absence of GLP-2R in central appetite circuits.

What Is Currently Known

Early preclinical data suggests GLP-3 may have some insulinotropic activity, a possible role in stimulating insulin secretion, and there is speculative interest in gut function modulation. Some in vitro studies have detected binding activity consistent with a dedicated receptor, but unlike GLP-1R and GLP-2R, no sequence-confirmed, expression-mapped GLP-3 receptor has been characterised at the level of GLP-1R or GLP-2R as of the current literature. Receptor cloning and selective agonist tool development are necessary steps that have not yet been published at the level required for confident mechanistic conclusions.

Pipeline and Evidence Gap

No GLP-3 receptor agonist has reached clinical trials as a drug candidate as of 2025–2026. The compound is not yet at a stage where pipeline discussion is meaningful beyond noting early academic interest. Researchers encountering GLP-3 in literature should treat claims about its mechanism or effects with proportionate scepticism: the evidence base is substantially thinner than for GLP-1 or GLP-2, and the receptor itself is not yet fully characterised. This is an honest evidence gap, not a pharmacological failure, GLP-3's biology may prove interesting once the receptor is properly defined.